Compare FPH & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPH | ACRS |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.2M | 311.0M |
| IPO Year | 2013 | 2015 |
| Metric | FPH | ACRS |
|---|---|---|
| Price | $5.45 | $3.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 176.1K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $237,926,000.00 | $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | ★ 12.37 | N/A |
| 52 Week Low | $4.58 | $1.05 |
| 52 Week High | $6.64 | $4.89 |
| Indicator | FPH | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.72 | 43.84 |
| Support Level | $5.36 | $2.78 |
| Resistance Level | $5.74 | $3.46 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 35.63 | 44.53 |
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its three reportable segments are Valencia, San Francisco, and Great Park. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.